Randomized phase III trial comparing ABVD plus radiotherapy with the Stanford V regimen in patients with stages I or II locally extensive, bulky mediastinal Hodgkin lymphoma: A subset analysis of the North American Intergroup E2496 trial

Journal of Clinical Oncology

Volumn 33, Issue 17, 2015, Pages 1936-1942

  Advani, Ranjana H ^a   Hong, Fangxin ^b   Fisher, Richard I ^c   Bartlett, Nancy L ^d   Robinson, K Sue ^e   Gascoyne, Randy D ^f   Wagner, Henry ^h   Stiff, Patrick J ⁱ   Cheson, Bruce D ^k   Stewart, Douglas A ^g   Gordon, Leo I ^j   Kahl, Brad S ^l   Friedberg, Jonathan W ^c   Blum, Kristie A ^m   Habermann, Thomas M ⁿ   Tuscano, Joseph M ^o   Hoppe, Richard T ^a   Horning, Sandra J ^a  

^a STANFORD CANCER INSTITUTE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

^g Tim Baker Cancer Institute   (Canada)

^h PENN STATE CANCER INSTITUTE   (United States)

ⁱ LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^j NORTHWESTERN UNIVERSITY   (United States)

^k GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^l UNIVERSITY OF WISCONSIN MADISON   (United States)

^m OHIO STATE UNIVERSITY   (United States)

ⁿ MAYO CLINIC   (United States)

^o UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; PROCARBAZINE;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BRAIN CANCER; BREAST CANCER; BULKY MEDIASTINAL HODGKIN LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG FATALITY; DRUG INDUCED CANCER; FAILURE FREE SURVIVAL; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; KIDNEY CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM CANCER; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SECOND CANCER; SENSORY NEUROPATHY; SEPSIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ADJUVANT RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MEDIASTINAL NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; NORTH AMERICA; PATHOLOGY; RISK FACTOR;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DACARBAZINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FEMALE; HODGKIN DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MECHLORETHAMINE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; NORTH AMERICA; PREDNISONE; PROCARBAZINE; RADIOTHERAPY, ADJUVANT; RISK FACTORS; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE;

EID: 84937133668     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.8138     Document Type: Article

References (35)

1. Hughes-Davies L, Tarbell NJ, Coleman CN, et al: Stage IA-IIB Hodgkin's disease: Management and outcome of extensive thoracic involvement. Int J Radiat Oncol Biol Phys 39:361-369, 1997
2. Mauch P, Goodman R, Hellman S: The significance of mediastinal involvement in early stage Hodgkin's disease. Cancer 42:1039-1045, 1978
3. Bonfante V, Santoro A, Viviani S, et al: Early stage Hodgkin's disease: Ten-year results of a non-randomised study with radiotherapy alone or combined with MOPP. Eur J Cancer 29A:24-29, 1992
4. Lister TA, Crowther D, Sutcliffe SB, et al: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7:1630-1636, 1989
5. Bradley AJ, Carrington BM, Lawrance JA, et al: Assessment and significance of mediastinal bulk in Hodgkin's disease: Comparison between computed tomography and chest radiography. J Clin Oncol 17:2493-2498, 1999
6. Kriz J, Mueller RP, Mueller H, et al: Large mediastinal tumor mass as a prognostic factor in Hodgkin's lymphoma: Is the definition on the basis of a chest radiograph in the era of CT obsolete? Strahlenther Onkol 188:1020-1024, 2012
7. National Comprehensive Cancer Network (NCCN): NCCN Clinical Practice Guidelines in Oncology: Hogkin Lymphoma Version 2.2014, 2014
8. Noordijk EM, Carde P, Dupouy N, et al: Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: Long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 24:3128-3135, 2006
9. von Tresckow B, Plütschow A, Fuchs M, et al: Dose-intensification in early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 30:907-913, 2012
10. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395, 2003
11. Gordon LI, Hong F, Fisher RI, et al: Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: An intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 31:684-691, 2013
12. Horning SJ, Hoppe RT, Breslin S, et al: Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial. J Clin Oncol 20:630-637, 2002
13. Koontz MZ, Horning SJ, Balise R, et al: Risk of therapy-related secondary leukemia in Hodgkin lymphoma: The Stanford University experience over three generations of clinical trials. J Clin Oncol 31:592-598, 2013
14. Horning SJ, Williams J, Bartlett NL, et al: Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492. J Clin Oncol 18:972-980, 2000
15. Kaplan EL, Meier P: Nonparametric estimation of incomplete observations. J Am Stat Assoc 53:457-481, 1958
16. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-220, 1972
17. Advani RH, Hoppe RT, Maeda LS, et al: Stage I-IIA non-bulky Hodgkin's Lymphoma: Is further distinction based on prognostic factors useful? The Stanford Experience. Int J Radiat Oncol Biol Phys 81:1374-1379, 2011
18. Edwards-Bennett SM, Jacks LM, Moskowitz CH, et al: Stanford V program for locally extensive and advanced Hodgkin lymphoma: The Memorial Sloan-Kettering Cancer Center experience. Ann Oncol 21:574-581, 2010
19. Hoskin PJ, Lowry L, Horwich A, et al: Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol 27:5390-5396, 2009
20. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998
21. Glimelius I, Molin D, Amini RM, et al: Bulky disease is the most important prognostic factor in Hodgkin lymphoma stage IIB. Eur J Haematol 71: 327-333, 2003
22. Thomas K, Ferme C, Noordijk EM, et al: Results of the EORTC-GELA H9 randomized trials: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL). Haematologica 92, 2007 (abstr C010)
23. Reference deleted
24. Eich HT, Diehl V, Görgen H, et al: Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28: 4199-4206, 2010
25. Diehl V, Behringer K: Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma (HL)? Cancer Invest 24:713-717, 2006
26. Engert A, Diehl V, Franklin J, et al: Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27:4548-4554, 2009
27. Borchmann P, Haverkamp H, Diehl V, et al: Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: Final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 29:4234-4242, 2011
28. Engert A, Haverkamp H, Kobe C, et al: Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial. Lancet 379:1791-1799, 2012
29. Bauer K, Skoetz N, Monsef I, et al: Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev 8:CD007941, 2011
30. th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012. Leuk Lymphoma 55:31-37, 2014
31. Connors JM, Benard F, Gascoyne RD, et al: FDG PET/CT scan guided treatment of limited stage Hodgkin lymphoma spares > 80% of patients from radiotherapy while retaining excellent disease control. Haematologica 95:S15, 2010
32. Picardi M, De Renzo A, Pane F, et al: Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma 48:1721-1727, 2007
33. Raemaekers JM, André MP, Federico M, et al: Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol 32:1188-1194, 2014
34. Younes A, Gopal AK, Smith SE, et al: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 30:2183-2189, 2012
35. Ansell SM, Connors JM, Park SI, et al: Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma. Blood 120, 2012 (abstr 798)